Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 8/2010

01-08-2010 | Original Paper

Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy

Authors: Jun Dang, Guang Li, Xiaobe Lu, Lei Yao, Shuo Zhang, Zhan Yu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2010

Login to get access

Abstract

Purpose

To investigate the correlation among DVH (lung dose–volume histogram) parameters, clinical factors, and grade ≥ 2 radiation pneumonitis (RP) in patients with locally advanced non-small-cell lung cancer (NSCLC) treated with three-dimensional conformal radiotherapy (3D-CRT), and the differences between patients treated with 3D-CRT alone or that combined with chemotherapy on RP.

Patients and methods

As much as 93 patients of stage III NSCLC were treated with 3D-CRT, among which 36 were treated with chemotherapy after 3D-CRT, 57 received 3D-CRT treatment alone. The radiation dose was 62.5–65 Gy (BED = 68–72.7 Gy).

Results

The morbidity of grade ≥ 2 RP was 49.5%, of which grade 2 and grade 3 were 33.3 and 16.1%, respectively. The morbidity of RP in those patients treated with chemotherapy after radiotherapy was evidently higher than that of patients treated with radiotherapy alone (61.1 vs. 42.1%). According to the single factor analysis, V5–V50 and MLD of both the ipsilateral and the whole lung were all related to the occurrence of RP; comparing grade 3 with grade 2 within the same group, except V45, V50, TV20, TV30, and TMLD, other parameters also had their statistical significance (P < 0.01); comparing the non-chemotherapy-treated group with the chemotherapy-treated group, TV30 and TV35 had their statistical significance. According to logistic regression analysis; the occurrence of RP was evidently associated with the comprehensive value of DVH parameters, chemotherapy, and gender. Chemotherapy has increased the risk of RP 7.6 times. The increase of each score in the comprehensive value of DVH parameters would increase the risk of RP 22.7 times.

Conclusion

The comprehensive values of DVH parameters, chemotherapy, and gender have independent effects on the occurrence of RP. Most of DVH parameters were associated with the occurrence of RP. The curve shape composed of multiple points in DVH parameters was more important than any single DVH parameter.
Literature
go back to reference Blom-Goldman U, Svane G, Wennberg B et al (2007) Quantitative assessment of lung density changes after 3-D radiotherapy for breast cancer. Acta Oncol 46(2):187–193CrossRefPubMed Blom-Goldman U, Svane G, Wennberg B et al (2007) Quantitative assessment of lung density changes after 3-D radiotherapy for breast cancer. Acta Oncol 46(2):187–193CrossRefPubMed
go back to reference Choi YW, Munden RF, Erasmus JJ et al (2004) Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics 24:985–998CrossRefPubMed Choi YW, Munden RF, Erasmus JJ et al (2004) Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics 24:985–998CrossRefPubMed
go back to reference Gopal R (2005) Pulmonary toxicity associated with the treatment of non-small cell lung cancer and the effects of cytoprotective strategies. Semin Oncol 32(2 Suppl 3):S55–S59CrossRefPubMed Gopal R (2005) Pulmonary toxicity associated with the treatment of non-small cell lung cancer and the effects of cytoprotective strategies. Semin Oncol 32(2 Suppl 3):S55–S59CrossRefPubMed
go back to reference Gopal R, Tucker SL, Komaki R et al (2003) The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys 56:106–113PubMed Gopal R, Tucker SL, Komaki R et al (2003) The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys 56:106–113PubMed
go back to reference Graham MV (1997) Predicting radiation response. Int J Radiat Oncol Biol Phys 39:561–562PubMed Graham MV (1997) Predicting radiation response. Int J Radiat Oncol Biol Phys 39:561–562PubMed
go back to reference Hernando ML, Marks LB, Bentel GC et al (2001) Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51:650–659PubMed Hernando ML, Marks LB, Bentel GC et al (2001) Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51:650–659PubMed
go back to reference Kim TH, Cho KH, Pyo HR et al (2005) Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 235:208–215CrossRefPubMed Kim TH, Cho KH, Pyo HR et al (2005) Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 235:208–215CrossRefPubMed
go back to reference Madani I, De Ruyck K, Goeminne H, De Neve W, Thierens H, Van Meerbeeck J (2007) Predicting risk of radiation-induced lung injury. J Thorac Oncol 2(9):864–874CrossRefPubMed Madani I, De Ruyck K, Goeminne H, De Neve W, Thierens H, Van Meerbeeck J (2007) Predicting risk of radiation-induced lung injury. J Thorac Oncol 2(9):864–874CrossRefPubMed
go back to reference Marks LB, Munley MT, Bentel GC et al (1997) Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 39:563–570PubMed Marks LB, Munley MT, Bentel GC et al (1997) Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 39:563–570PubMed
go back to reference Oetzel D, Schraube P, Hensley F et al (1995) Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 33:455–460PubMed Oetzel D, Schraube P, Hensley F et al (1995) Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 33:455–460PubMed
go back to reference Onishi H, Kuriyama K, Yamaguchi M et al (2003) Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage Ш non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 40:79–84CrossRefPubMed Onishi H, Kuriyama K, Yamaguchi M et al (2003) Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage Ш non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 40:79–84CrossRefPubMed
go back to reference Piotrowski T, Matecka-Nowak M, Milecki P (2005) Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy. Neoplasma 52(1):56–62PubMed Piotrowski T, Matecka-Nowak M, Milecki P (2005) Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy. Neoplasma 52(1):56–62PubMed
go back to reference Rengan R, Rosenzweig KE, Venkatraman E et al (2004) Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiol Oncol Biol Phys 60:741–747CrossRef Rengan R, Rosenzweig KE, Venkatraman E et al (2004) Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiol Oncol Biol Phys 60:741–747CrossRef
go back to reference Robnett TJ, Machtay M, Vines EF et al (2004) Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 48:89–94CrossRef Robnett TJ, Machtay M, Vines EF et al (2004) Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 48:89–94CrossRef
go back to reference Schallenkamp JM, Miller RC, Brinkmann DH et al (2007) Incidence of radiation pneumonitis after thoracic irradiation: dose-volume correlates. Int J Radiat Oncol Biol Phys 67(2):410–416PubMed Schallenkamp JM, Miller RC, Brinkmann DH et al (2007) Incidence of radiation pneumonitis after thoracic irradiation: dose-volume correlates. Int J Radiat Oncol Biol Phys 67(2):410–416PubMed
go back to reference Seppenwoolde Y, Lebesque JV, De Jaeger K et al (2003) Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys 56:106–113CrossRef Seppenwoolde Y, Lebesque JV, De Jaeger K et al (2003) Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys 56:106–113CrossRef
go back to reference Sim S, Rosenzweig KE, Schindelheim R et al (2001) Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 51:660–665PubMed Sim S, Rosenzweig KE, Schindelheim R et al (2001) Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 51:660–665PubMed
go back to reference Tsujino K, Hirota S, Kotani Y et al (2006) Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: dose-volume histogram analysis and comparison with conventional chemoradiation. Int J Radiat Oncol Biol Phys 64(4):1100–1105PubMed Tsujino K, Hirota S, Kotani Y et al (2006) Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: dose-volume histogram analysis and comparison with conventional chemoradiation. Int J Radiat Oncol Biol Phys 64(4):1100–1105PubMed
go back to reference Wang S, Liao Z, Wei X et al (2006) Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 66(5):1399–1407PubMed Wang S, Liao Z, Wei X et al (2006) Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 66(5):1399–1407PubMed
go back to reference Weibai Y (2008) Radiation oncology, vol 4. Peking Union Medical College Publishing Company, Beijing, pp 645–652. ISBN978-7-81072-948-2 Weibai Y (2008) Radiation oncology, vol 4. Peking Union Medical College Publishing Company, Beijing, pp 645–652. ISBN978-7-81072-948-2
go back to reference Willner J, Jost A, Baier K et al (2003) A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy. Strahlenther Onkol 179:548–556CrossRefPubMed Willner J, Jost A, Baier K et al (2003) A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy. Strahlenther Onkol 179:548–556CrossRefPubMed
go back to reference Yamashita H, Nakagawa K, Nakamura N (2007) Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2:21–32CrossRefPubMed Yamashita H, Nakagawa K, Nakamura N (2007) Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2:21–32CrossRefPubMed
go back to reference Yorke ED, Jackson A, Rosenzweig KE et al (2002) Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 54:329–339CrossRefPubMed Yorke ED, Jackson A, Rosenzweig KE et al (2002) Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 54:329–339CrossRefPubMed
go back to reference Zhao LJ, West B, Hayman JA et al (2007) High radiation dose may reduce the negative effect of large gross tumor volume in patients with early stage non-small cell lung cancer]. Int J Radiat Oncol Biol Phys 68:103–110PubMed Zhao LJ, West B, Hayman JA et al (2007) High radiation dose may reduce the negative effect of large gross tumor volume in patients with early stage non-small cell lung cancer]. Int J Radiat Oncol Biol Phys 68:103–110PubMed
go back to reference Zhu XZ, Wang LH, Zhao LJ et al (2008) Impact of gross tumor volume and radiation therapy dose on survival in stage III non-small-cell lung cancer treated with three-dimensional radiation therapy. Chin J Radiat Oncol 17(1):26–29 Zhu XZ, Wang LH, Zhao LJ et al (2008) Impact of gross tumor volume and radiation therapy dose on survival in stage III non-small-cell lung cancer treated with three-dimensional radiation therapy. Chin J Radiat Oncol 17(1):26–29
Metadata
Title
Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy
Authors
Jun Dang
Guang Li
Xiaobe Lu
Lei Yao
Shuo Zhang
Zhan Yu
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 8/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0764-4

Other articles of this Issue 8/2010

Journal of Cancer Research and Clinical Oncology 8/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.